Avantor, Inc. (AVTR) Earnings Call Analysis

NYSE · Healthcare · Medical Instruments & Supplies

19/25

Growth 4 Margin 3 Expansion 4 Platform 3 Financial 5

latest quarter score

Earnings Reports

19
Avantor (AVTR) Q2 2026: VWR Organic Growth Turns Positive, Setting Stage for H2 Acceleration
July 29, 2026
8
Avantor (AVTR) Q4 2025: VWR Relaunch and $35M Targeted Investment Signal Strategic Channel Reset
June 15, 2026
9
Avantor (AVTR) Q1 2026: VWR Stabilizes as 25% Leadership Refresh Targets Back-Half Turnaround
April 29, 2026
9
Avantor (AVTR) Q3 2025: $785M Lab Goodwill Impairment Signals Urgent Turnaround Push
October 29, 2025
10
Avantor (AVTR) Q2 2025: $100M Share Gains Offset by Margin Compression as Pricing War Intensifies
August 01, 2025
11
Avantor (AVTR) Q1 2025: Cost Transformation Target Lifted to $400M as Lab Solutions Stalls
July 06, 2025
Avantor (AVTR) Q3 2024: Free Cash Flow Guidance Raised 20% as Bioprocessing Orders Accelerate
October 25, 2024
Avantor (AVTR) Q2 2024: Bioprocessing Orders Drive High-Single Digit Sequential Growth
July 26, 2024
Avantor (AVTR) Q1 2024: Cost Transformation Delivers $75M Savings Trajectory, Margin Ramp De-Risked
April 26, 2024
Avantor (AVTR) Q4 2023: $300M Cost Program Targets Margin Upside Amidst 4.8% Organic Decline
February 14, 2024
Avantor (AVTR) Q3 2023: Free Cash Flow Conversion Tops 110% as Inventory Normalizes
October 27, 2023
Avantor (AVTR) Q2 2023: Biopharma and Semiconductor Declines Drive 6.5% Core Organic Drop, Margin Resilience Signals Cost Discipline
July 28, 2023
Avantor (AVTR) Q1 2023: Destocking Drives 300bps Guide Cut, Margin Defends at 19.4%
April 28, 2023

Browse all companies